Default company panoramic image
7a26317d d822 45e5 bca0 b610ab42fee4

Iowa Approach

Iowa Approach developed an ultra-fast, less risky, and more cost-effective way to perform catheter-based atrial fibrillation (AF) ablation.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Iowa City, IA, USA
  • Currency USD
  • Founded January 2012
  • Website

Company Summary

Iowa Approach is developing proprietary medical devices for treating one of the world’s most common heart rhythm disorders, atrial fibrillation. Patents for several of these devices have been filled with priority dating to August 18th 2012 on behalf of the University of Iowa Research Foundation (UIRF), and an exclusive, world-wide license agreement has been finalized with UIRF. UIRF estimates revenues $150-200M within 5-years of market entry.


  • Default avatar
    Dr. Steven Mickelsen

    Dr. Steven Mickelsen is a physician inventor with 15 years of research experience in heart rhythm. He was a Howard Hughes Research Scholar at the National Heart, Lung, and Blood Institute (NHLBI) from 2004-2005, trained in Internal Medicine at Mayo Clinic from 2007-2010, and is now at University of Iowa Hospitals/Clinics (UIHC) as a Cardiovascular Fellow. He has published many peer-reviewed articles and is uniquely qualified.

  • Default avatar
    Dr. Howard Dittrich

    Dr Dittrich, graduated from the UI CCOM in 1978 after receiving his BS from UI in 1975. Following residency in internal medicine at UC San Diego, he received his cardiology training at St Thomas Hospital in London and UC San Diego. He has been involved in multiple start-up companies as CMO including NovaCardia, acquired in 2007 by Merck & Co., Corthera, acquired in 2009 by Novartis, and TargeGen, acquired in 2010 by Sanofi Aventis.

  • Default avatar
    John Slump

    John Slump, B.B.A. Finance, is a medical device entrepreneur with CFO-level expertise. John is currently CFO & Founder of Corvida Medical, a device company commercializing an Innovative Device to Improve Safety of Preparing and Administering Chemotherapy. In this role, Slump sourced $10 million via angel/VC investors, NIH SBIR grants, etc., negotiated agreements with leading hospitals, and recruited CEO and COO-level leadership for the company.


  • Default avatar
    Greg Williams-Simmons Perrine (IP); Bill McCartan-Bradley Riley (corporate/securities)
    Default avatar